Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported a bona fide gift of common stock. On the reported date, Ming transferred 135,892 shares of Cytek Biosciences common stock as a gift at a stated price of $0.00 per share. After this disposition, Ming continued to hold 4,796,688 shares of common stock directly, indicating that the gifted amount represents a relatively small portion of his overall reported holdings. As a gift transaction, this Form 4 reflects a non-market transfer rather than an open-market purchase or sale.
Cytek Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. Of 129,142,587 common shares outstanding as of April 13, 2026, 111,161,490 were present or represented by proxy, about 86.1% of shares entitled to vote, establishing a strong quorum.
Three director nominees received more votes for than withheld: Vera Imper, Ph.D. (64,769,976 for; 20,723,477 withheld), Glenn P. Muir (79,599,103 for; 5,894,350 withheld) and Ming Yan, Ph.D. (76,741,063 for; 8,752,390 withheld). Two additional matters were also approved, including one that received 84,794,380 votes for and another that received 110,533,253 votes for, each with relatively few votes against.
Cytek Biosciences director Jack Ball exercised a vested equity award for 43,973 shares of common stock through conversion of Restricted Stock Units. The RSU award fully vested on June 10, 2026, and after this non‑market, compensation-related transaction he directly holds 86,678 shares of Cytek common stock.
Cytek Biosciences director Glenn P. Muir reported equity awards that increase his potential ownership in the company. He received a stock option for 29,835 shares of common stock at an exercise price of $4.05 per share, expiring on June 10, 2036. He also received 55,555 restricted stock units, each representing one share of common stock.
The option vests in equal monthly installments over three years following the June 10, 2026 grant date. The restricted stock units vest in tranches between August 18, 2026 and August 18, 2027 based on a detailed schedule, tying full ownership to continued service.
Cytek Biosciences, Inc. director Glenn P. Muir filed an initial Form 3 beneficial ownership report. The filing identifies him as a director but shows no share purchases, sales, option exercises, gifts, or restructurings, and no derivative positions or holdings are detailed in the provided data.
Cytek Biosciences, Inc. director Richard Chin reported receiving new equity awards as part of his board compensation. He was granted an option for 18,261 shares of common stock at an exercise price of $4.05 per share, expiring on June 10, 2036. He also received 33,333 restricted stock units, each representing one share of common stock. Both the option and RSU award vest 100% on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting, if that meeting is held in June 2027. These are compensation-related grants, not open-market purchases or sales.
Cytek Biosciences director Imper Vera increased her equity stake through compensation-related awards. On June 10, 2026, she exercised 43,973 Restricted Stock Units that had fully vested the same day, receiving an equal number of common shares and bringing her direct common stock holdings to 59,679 shares.
She also received grants of 18,261 director stock options with a $4.05 exercise price expiring on June 10, 2036, and 33,333 new Restricted Stock Units. Both the new option and RSU awards vest 100% on the earlier of June 10, 2027 or Cytek’s 2027 annual meeting of stockholders, if that meeting is held in June 2027. No open-market buys or sales were reported.
Cytek Biosciences director Deborah J. Neff increased her equity stake through compensation-related transactions. On June 10, 2026, she exercised previously granted restricted stock units, receiving 43,973 shares of common stock and bringing her direct holdings to 59,679 shares.
On the same date, she received a director stock option for 18,261 shares of common stock at an exercise price of $4.05 per share, expiring on June 10, 2036. She was also granted 33,333 new restricted stock units, each representing one share of common stock, which are scheduled to vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders if held in June 2027.
Cytek Biosciences director Michael Holder reported equity compensation activity. He exercised 43,973 Restricted Stock Units into Common Stock, and following these transactions he holds 60,694 Common Stock shares directly. The filing shows no open‑market buys or sells.
Holder also received a grant of 18,261 director stock options with a $4.05 exercise price, expiring on June 10, 2036. In addition, he was granted 33,333 new RSUs. Both the new option grant and RSUs are scheduled to vest 100% on the earlier of June 10, 2027 or Cytek’s 2027 annual meeting of stockholders, if that meeting is held in June 2027.
Cytek Biosciences, Inc. reported that Philippe Busque, Ph.D. has submitted his resignation as Senior Vice President, Global Sales and Services. His resignation is effective June 5, 2026 and is described as being to pursue another career opportunity, with no disagreements regarding the company’s operations, policies or practices.